INYX MANUFACTURES ANTI-INFLAMMATORY FOAM FOR COLITIS.Inyx, Inc. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB: IYXI), Miami, Fla., a manufacturer and developer of specialized drug delivery pharmaceutical products, has developed an anti-inflammatory foam for launch into the German market for a leading German pharmaceutical manufacturer and distributor. Inyx's wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. , INyX Pharma Limited ("INyX Pharma") has successfully manufactured a non-steroidal anti-inflammatory foam for use in treatment of ulcerative colitis This article concerns the treatment of ulcerative colitis, a form of inflammatory bowel disease (IBD). Ulcerative colitis is a form of colitis, a disease of the intestine, specifically the large intestine or colon, that includes characteristic ulcers, or open sores, in the colon. , which is a chronic disease of unknown origin that causes inflammation and ulcers in the lining of the large intestine large intestine End section of the intestine. It is about 5 ft (1.5 m) long, is wider than the small intestine, and has a smooth inner wall. In the first half, enzymes from the small intestine complete digestion, and bacteria produce many B vitamins and vitamin K. . An estimated one million people worldwide have the disease, with an estimated one in 600 people on average, in Europe. The product, which acts locally to reduce inflammation, is a metered dose foam that is applied with a rectal applicator ap·pli·ca·tor n. An instrument for applying something, such as a medication. applicator, n a device for applying medication; usually a slender rod of glass or wood, used with a pledget of cotton on the end. . Steven J. Handley, president of Inyx said, "We are extremely pleased to have established this new relationship with a major European client that uses specialized metered dose anti-inflammatory foams for drug delivery. The timely supply of this product for a major launch is an example of how we leverage Inyx's expertise in niche aerosol and spray technologies and combine it with a strong customer service focus." "Moreover, the production volume required for the contract increases the productivity of our new hydrocarbon aerosol line, recently validated to meet European and US regulatory requirements. The new production capability enables us to meet a wide range of product requirements in the foam and mousse dermatological areas," said Handley. This anti-inflammatory foam expands Inyx's participation in the gastroenterological sector of the dermatology market. Non-steroidal anti- inflammatory prescription dermatology products are estimated to account for nearly 15% of the worldwide $9 billion dermatology market. As these markets continue to expand, we will continue with our strategic aim of partnering with clients and exploiting niche market A niche market also known as a target market is a focused, targetable portion (subset) of a market sector. By definition, then, a business that focuses on a niche market is addressing a need for a product or service that is not being addressed by mainstream providers. opportunities. Inyx is one of the few pharmaceutical companies in the world that is equipped to produce pharmaceutical aerosol products in a metered dose foam format. The technological advances, incorporated in the Inyx production facility, located near Manchester England, makes possible the manufacture and introduction of new innovative drug delivery systems. About Inyx, Inc. Inyx, Inc. is a development and contract manufacturer of specialized drug delivery pharmaceutical products with a focus on pursuing strategic investment opportunities. The company is focused on acquiring and/or investing in a number of sectors within the pharmaceutical, biotechnology and medical devices industries. These include research and development, manufacturing, distribution, and intellectual property acquisitions. Key acquisition targets include high quality manufacturing operations Manufacturing operations concern the operation of a facility, as opposed to maintenance, supply and distribution, health, and safety, emergency response, human resources, security, information technology and other infrastructural support organizations. that offer complementary services to its current sterile fill and drug delivery capabilities. Headquartered in Miami, Florida “Miami” redirects here. For the Native American tribe, see Miami tribe. Miami is a major city in southeastern Florida, in the United States. It is the county seat of Miami-Dade County. Miami is a gamma world city with an estimated population of 404,048. , Inyx, Inc. operates R&D and production facilities in Runcorn, near Manchester, England. Acquired at the end of April 2003, INyX Pharma Limited, a subsidiary of the company, is a specialty pharmaceutical company that focuses its expertise on development-led contract manufacturing in the sterile pharmaceutical, finished dosage-form, outsourcing sector. INyX Pharma specializes in niche products and technologies for the treatment of respiratory, allergy, dermatological and topical conditions. INyX Pharma's client base comprises blue-chip ethical pharmaceutical companies, branded generic firms and biotechnology groups. INyX Pharma manufactures for a majority of global markets including North America North America, third largest continent (1990 est. pop. 365,000,000), c.9,400,000 sq mi (24,346,000 sq km), the northern of the two continents of the Western Hemisphere. , Europe, Latin America Latin America, the Spanish-speaking, Portuguese-speaking, and French-speaking countries (except Canada) of North America, South America, Central America, and the West Indies. and the Middle East. For more information, call 305/789-6649 or visit http://www.inyxinc.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion